Priya Koppikar

2.6k total citations
28 papers, 1.2k citations indexed

About

Priya Koppikar is a scholar working on Genetics, Oncology and Molecular Biology. According to data from OpenAlex, Priya Koppikar has authored 28 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Genetics, 11 papers in Oncology and 10 papers in Molecular Biology. Recurrent topics in Priya Koppikar's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (17 papers), Chronic Myeloid Leukemia Treatments (8 papers) and Cytokine Signaling Pathways and Interactions (8 papers). Priya Koppikar is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (17 papers), Chronic Myeloid Leukemia Treatments (8 papers) and Cytokine Signaling Pathways and Interactions (8 papers). Priya Koppikar collaborates with scholars based in United States, Hong Kong and China. Priya Koppikar's co-authors include Ross L. Levine, Omar Abdel‐Wahab, Rita Mulherkar, Neha Bhagwat, Ayalew Tefferi, Sachie Marubayashi, Vivian Wai Yan Lui, Xinyang Zhao, Lan Wang and Sílvia Menéndez and has published in prestigious journals such as Journal of Clinical Investigation, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Priya Koppikar

26 papers receiving 1.2k citations

Peers

Countries citing papers authored by Priya Koppikar

Since Specialization

Citations

This map shows the geographic impact of Priya Koppikar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Priya Koppikar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Priya Koppikar more than expected).

Fields of papers citing papers by Priya Koppikar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Priya Koppikar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Priya Koppikar. The network helps show where Priya Koppikar may publish in the future.

Co-authorship network of co-authors of Priya Koppikar

This figure shows the co-authorship network connecting the top 25 collaborators of Priya Koppikar. A scholar is included among the top collaborators of Priya Koppikar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Priya Koppikar. Priya Koppikar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	NAMPT inhibition uncovers therapeutic vulnerabilities to venetoclax and chemotherapy in acute myelogenous leukemia 2025 ·Leukemia & lymphoma ·(unknown), Chaomei Liu, (unknown), Yanqing Huang, (unknown), Jyotsna Singh, Priya Koppikar, (unknown), Lisa S. St. John, Vinay K. Puduvalli, Jeffrey J. Molldrem, Palaniraja Thandapani, Nitin Jain, Rosa Lapalombella, Deepa Sampath	0
2	A Public Neoantigen Produced By the SF3B1 K700E Mutation Is a Bona Fide T Cell Target in AML/MDS 2023 ·Blood ·Noah Tubo, Duncheng Wang, Qiuming He, Yibin Chen, Ho Ngai, Yanqing Huang, (unknown), Xizeng Mao, Shoudan Liang, Hong He, Gheath Alatrash, Priya Koppikar, Jeffrey J. Molldrem	0
3	Jak1 Integrates Cytokine Sensing to Regulate Hematopoietic Stem Cell Function and Stress Hematopoiesis 2017 ·Cell stem cell ·Maria Kleppe, Matthew H. Spitzer, Sheng Li, Corinne E. Hill, Lauren Dong, Efthymia Papalexi, (unknown), Robert L. Bowman, Matthew D. Keller, Priya Koppikar, Franck Rapaport, Julie Teruya‐Feldstein, Jorge Gandara, Christopher E. Mason, Garry P. Nolan, Ross L. Levine	50
4	Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition 2015 ·Nature Medicine ·Qiang Wen, Qiong Yang, Benjamin Goldenson, Sébastien Malinge, Terra L. Lasho, Rebekka K. Schneider, Lawrence J. Breyfogle, (unknown), Laure Gilles, Priya Koppikar, Omar Abdel‐Wahab, Animesh Pardanani, Brady L. Stein, Sandeep Gurbuxani, Ann Mullally, Ross L. Levine, Ayalew Tefferi, John D. Crispino	113
5	Type II Inhibition of JAK2 with NVP-CHZ868 Reverses Type I JAK Inhibitor Persistence and Demonstrates Increased Efficacy in MPN Models 2014 ·Blood ·Sara C. Meyer, Matthew D. Keller, Priya Koppikar, Olga A. Guryanova, Maria Kleppe, Anna Sophia McKenney, William R. Sellers, Francesco Hofmann, Fabienne Baffert, Christoph Gaul, Thomas Radimerski, Ross L. Levine	4
6	Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms 2014 ·Blood ·Neha Bhagwat, Priya Koppikar, Matthew D. Keller, Sachie Marubayashi, Kaitlyn Shank, Raajit K. Rampal, Jun Qi, Maria Kleppe, Hardik J. Patel, Smit Shah, Tony Taldone, James E. Bradner, Gabriela Chiosis, Ross L. Levine	84
7	Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms 2013 ·International Journal of Hematology ·Neha Bhagwat, Ross L. Levine, Priya Koppikar	33
8	AKT is a therapeutic target in myeloproliferative neoplasms 2013 ·Leukemia ·Irum Khan, Zan Huang, Qing Wen, Monika J. Stankiewicz, (unknown), Benjamin Goldenson, Roger A. Schultz, Lauren Diebold, Sandeep Gurbuxani, Christy M. Finke, Terra L. Lasho, Priya Koppikar, Animesh Pardanani, Brady L. Stein, Jessica K. Altman, Ross L. Levine, Ayalew Tefferi, John D. Crispino	62
9	Combination Therapy Using JAK2 and HSP90 Inhibitors Increased Efficacy in Myelofibrosis in Vivo 2012 ·Blood ·Ross L. Levine, Priya Koppikar, Sachie Marubayashi, Neha Bhagwat, Tony Taldone, Christopher Y. Park, Gabriela Chiosis	4
10	JAK2V617F-Mediated Phosphorylation of PRMT5 Downregulates Its Methyltransferase Activity and Promotes Myeloproliferation 2011 ·Cancer Cell ·Fan Liu, Xinyang Zhao, Fabiana Perna, Lan Wang, Priya Koppikar, Omar Abdel‐Wahab, Michael W. Harr, Ross L. Levine, Hao Xu, Ayalew Tefferi, A DeBlasio, Megan Hatlen, Sílvia Menéndez, Stephen D. Nimer	219
11	Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell–stimulated T cells yet preserves immunity to recall antigen 2011 ·Blood ·Brian C. Betts, Omar Abdel‐Wahab, Shane A. Curran, (unknown), Priya Koppikar, Glenn Heller, Ross L. Levine, James W. Young	71
12	Induction of Megakaryocyte Polyploidization in Combination with JAK Inhibition As a Novel Therapeutic Strategy for Myeloproliferative Neoplasms 2011 ·Blood ·Qiang Wen, Benjamin Goldenson, Sébastien Malinge, Priya Koppikar, Ross L. Levine, Ayalew Tefferi, John D. Crispino	2
13	Inhibition of AKT Signaling Potently Inhibits the Growth of JAK and MPL-Mutant Cells in the Myeloproliferative Neoplasms In Vitro and In Vivo, 2011 ·Blood ·Irum Khan, Zan Huang, Qiang Wen, Priya Koppikar, Ross L. Levine, Ayalew Tefferi, John D. Crispino	1
14	HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans 2010 ·Journal of Clinical Investigation ·Sachie Marubayashi, Priya Koppikar, Tony Taldone, Omar Abdel‐Wahab, Nathan West, Neha Bhagwat, Eloisi Caldas-Lopes, Kenneth N. Ross, Mithat Gönen, (unknown), James H. Ahn, Anna Rodina, Ouathek Ouerfelli, Guangbin Yang, Cyrus V. Hedvat, James E. Bradner, Gabriela Chiosis, Ross L. Levine	142
15	Intratumoral Epidermal Growth Factor Receptor Antisense DNA Therapy in Head and Neck Cancer: First Human Application and Potential Antitumor Mechanisms 2009 ·Journal of Clinical Oncology ·Stephen Y. Lai, Priya Koppikar, Sufi M. Thomas, Erin E. Childs, Ann Marie Egloff, Raja R. Seethala, Barton F. Branstetter, William E. Gooding, Ashok Muthukrishnan, James M. Mountz, Vivian Wai Yan Lui, Dong M. Shin, Sanjiv S. Agarwala, (unknown), Larry A. Couture, Eugene N. Myers, Jonas T. Johnson, Gordon B. Mills, Athanassios Argiris, Jennifer R. Grandis	46
16	JAK2 and MPL Mutations in Myeloproliferative Neoplasms 2008 ·Acta Haematologica ·Priya Koppikar, Ross L. Levine	8
17	Constitutive Activation of Signal Transducer and Activator of Transcription 5 Contributes to Tumor Growth, Epithelial-Mesenchymal Transition, and Resistance to Epidermal Growth Factor Receptor Targeting 2008 ·Clinical Cancer Research ·Priya Koppikar, Vivian Wai Yan Lui, (unknown), Sichuan Xi, Raymond L. Chai, (unknown), (unknown), Jennifer R. Grandis	60
18	Antiproliferative Mechanisms of a Transcription Factor Decoy Targeting Signal Transducer and Activator of Transcription (STAT) 3: The Role of STAT1 2007 ·Molecular Pharmacology ·Vivian Wai Yan Lui, Amanda L. Boehm, Priya Koppikar, (unknown), Daniel E. Johnson, (unknown), Erin E. Childs, Maria L. Freilino, Jennifer R. Grandis	61
19	Activation of STAT5 contributes to tumor growth and epithelial-mesenchymal transition in head and neck cancer 2006 ·Cancer Research ·Vivian Wai Yan Lui, Sichuan Xi, (unknown), Priya Koppikar, Jennifer R. Grandis	1
20	Identification of human papillomaviruses in tumors of the oral cavity in an Indian community 2004 ·International Journal of Cancer ·Priya Koppikar, (unknown), Rita Mulherkar	78

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact